No Data
No Data
Avalo Therapeutics Welcomes New CMO With Competitive Package
Express News | Avalo Therapeutics Announces Appointment of DR. Mittie Doyle as Chief Medical Officer
Oppenheimer Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $35
Oppenheimer Remains a Buy on Avalo Therapeutics (AVTX)
Express News | Avalo Therapeutics Announces Prospectus For Sale Of Up To 22.4M Shares Of Common Stock And Series C Preferred Stock, Plus 12M Warrants By Selling Stockholders
Avalo Therapeutics | 10-Q/A: Quarterly report (Amendment)
No Data